Back to search results

Study of RMC-9805 for KRAS G12D-Mutant Solid Tumors

This study is testing two oral tablet medications, RMC-9805 and RMC-6236, for adults with advanced solid tumors that have a specific genetic change called a KRAS G12D-mutation. This includes non-small cell lung cancer, colorectal cancer, and pancreatic cancer. You may be able to join if your cancer has this mutation and has progressed after standard treatments. The study aims to understand how safe these drugs are, how well your body handles them, and if they show any signs of shrinking tumors. Researchers will be looking for side effects and how well the drugs are tolerated over time. The study is currently unclear on its recruitment status and plans to enroll up to 604 participants.

Study design
This is an open-label, multi-center study, meaning both you and your doctors will know which treatment you are receiving. It is a Phase 1/1b study, which typically focuses on safety and dosage, and includes two groups: one receiving RMC-9805 alone and another receiving RMC-9805 with RMC-6236.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Adverse events will be measured for up to 3 years, and Dose Limiting Toxicities will be measured at 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06040541

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Revolution Medicines, Inc.
~604 participants
Updated 2026-06-03 on ClinicalTrials.gov
What's tested:RMC-9805RMC-6236

At a glance

Recruiting sites
17 of 17 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events
Measured over Up to 3 years
+1 more outcome measured

Conditions

Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Advanced Solid Tumors

Explore related trials

Colorectal CarcinomaLung Non-Small Cell CarcinomaPancreatic Ductal AdenocarcinomaSolid NeoplasmGTPase KRas

Where it's being run

17 sites across 11 states
Texas3
Florida2
Massachusetts2
New York2
North Carolina2
California1
Connecticut1
Maryland1

Study leadership

  • Revolution Medicines, Inc. · STUDY_DIRECTOR · Revolution Medicines, Inc.

Who to contact

Revolution Medicines, Inc.
[email protected]
1-844-2-REVMED
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pathologically documented, locally advanced or metastatic solid tumor with a KRAS G12D-mutation
Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage
ECOG performance status 0 or 1
Adequate organ function

Exclusion

Primary central nervous system (CNS) tumors
Known or suspected leptomeningeal or active brain metastases or spinal cord compression
Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
Participant was previously treated with an investigational KRAS G12D inhibitor, pan- or multi-RAS inhibitor, or had prior therapy with any direct RAS-targeted therapy (eg, degraders and inhibitors)

What this trial measures

  • Adverse eventsUp to 3 years

    Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs, and vital signs

  • Dose Limiting Toxicities21 days

    Number of participants with Dose Limiting Toxicities (DLTs)